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broad substrate specificity (Barr et al.,
2009); the catalytic activities of PTPs have
been estimated to be 10- to 1000-fold
higher than that of tyrosine kinases
(discussedby Fischer et al., 1991). Another
contributing factor is the activity of inhibi-
tory kinases such as Csk, which also
constrain T cell activation (Schoenborn
et al., 2009). Progress in understanding
TCR triggering will require the teasing
apart of these and other competing
factors and the identification of those
factors with the largest impact on net
phosphorylation of the TCR. The effects
of pervanadate on phosphorylation levels
in resting T cells observed by ourselves
(Figures S1B and S1C) and by others
many years ago (e.g., O’Shea et al., 1992)
suggest that PTPs could be key. For us,
the sheer weight of the numbers also
warrants their serious consideration.SUPPLEMENTAL INFORMATION
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Multilayered Control of T Cell
Receptor PhosphorylationWe would like to respond to the Corre-
spondence by Fernandes et al., but first
we will summarize the data in our Cell
paper (Xu et al., 2008). Our study used
a biophysical approach to examine the
binding of the CD33 cytoplasmic domain
(CD33CD) to the plasma membrane. We
reported a new FRET assay to examine
CD33CD binding to the inner leaflet of
the plasma membrane in live Jurkat cells,
a transformed T cell line. Furthermore, we
developed an approach to determine
the NMR structure of CD33CD bound in
a lipid bilayer environment. The structure
showed that the two tyrosines of the im-munoreceptor tyrosine-based activation
motif (ITAM) partitioned into the hydro-
phobic core of the bilayer in a dynamic
manner, with substantial movement of
the two tyrosines and other elements of
the cytoplasmic domain (Figure 6, Xu
et al., 2008). Microscopy data yielded
similar FRET values for CD33CD tagged
with C-terminal teal fluorescent protein
(TFP) and for a positive control in which
TFP was in close proximity to the plasma
membrane (there was a three amino acid
linker between the transmembrane and
TFP domains). These data indicated that
most of the cytoplasmic domain wasmembrane bound in these transfected
nonstimulated Jurkat cells. However, we
did not claim that all CD33 cytoplasmic
domains in a given T cell are completely
bound to the plasma membrane. This
would be impossible in a biological sys-
tem because binding events always
follow equilibrium conditions, with the
size of the bound versus free fractions
being determined by the ratio of on and
off rates. It follows that changes in equilib-
rium can result in dissociation of CD33CD
from the membrane. Our data showed
a structure with substantial mobility in
which changes in equilibrium, such as
recruitment of the tyrosine kinase Lck,
could enable phosphorylation.
We wish to point out that we did not
claim that binding of CD33CD to the
membrane was the only mechanism that
prevents spontaneous T cell signaling.
It is well established that there is
multilayered control of T cell receptor
(TCR) signaling because completeeptember 3, 2010 ª2010 Elsevier Inc. 669
phosphorylationof evenoneor a fewTCRs
is sufficient to result in T cell activation
(Bergman et al., 1992; Davis and van der
Merwe, 2006). Without highly effective
mechanisms to prevent spontaneous
signaling, rampant chronic inflammation
and autoimmunity would result. Sponta-
neous signaling is inhibited by the Csk
kinase, which phosphorylates Lck kinase
at inhibitory tyrosine 505, as well as
multiple phosphatases (Bergman et al.,
1992; Davis and van der Merwe, 2006). In
agreement with Fernandes et al., we did
not detect phosphorylation of the
CD33CDEmut1+2mutant protein in Jurkat
cells (Figure S1B,CD33-Mut time0), which
was a negative control for the FRET exper-
iments. However, if binding of CD33
to themembrane togetherwith other inhib-
itory mechanisms guards against sponta-
neous phosphorylation, this result is not
surprising. Phosphorylation may only be
favored with appropriate TCR localization
into microclusters that exclude the CD45
phosphatase (Varma et al., 2006), as well
as simultaneous colocalization of active
Lck bound to CD4/CD8 coreceptors close
to the clustered TCR-CD3 complexes.
Fernandes et al. assume that the
CD33CD Emut1+2 mutant protein would
normally interact with Lck. However, the
loss of six basic residues substantially
changes its charge properties. We
therefore directly compared the phos-
phorylation of the mutant and wild-type
CD33CD proteins in an in vitro phosphor-
ylation assay with the purified cyto-
plasmic domains of the wild-type and
Emut1+2 proteins and purified Lck in the
absence of liposomes (Figure S1A). We
observed greatly reduced phosphoryla-
tion of the mutant protein, even though
equal amounts of wild-type and mutant
proteins were used. The mutant protein
was not detectably phosphorylated with
100 ng of Lck kinase and was only phos-
phorylated at low levels with 400 ng Lck;
the wild-type protein was robustly phos-
phorylated under both conditions. Fer-
nandes et al. also mention delayed phos-
phorylation kinetics for this mutant
protein in cells treated with pervanadate,
which inhibits a broad range of phospha-
tases (data not shown). We confirmed
this finding and observed substantially
delayed phosphorylation of the mutant
protein after pervanadate treatment: the
wild-type protein was phosphorylated670 Cell 142, September 3, 2010 ª2010 Elseafter 2 min, whereas phosphorylation of
the mutant was delayed, with a 3.5- to
5-fold reduction at 10 min (Figure S1B).
However, both proteins were phosphory-
lated to a similar degree at a later time
point (30 min), as Fernandes et al. also
showed. The greatly reduced interaction
of the mutant protein with Lck as well as
the multiple control mechanisms regu-
lating T cell activation could account for
the absence of observable phosphoryla-
tion of this particular CD33mutant in non-
stimulated Jurkat cells. It is not known
why mutation of six basic residues in the
N-terminal part of CD33CD reduces the
interaction with Lck, but conformational
changes in the cytoplasmic domain or
loss of long-range charge interactions
with Lck could be involved.
Pervanadate oxidizes the active site
cysteines of many different phosphatases
and is generated by mixing hydro-
gen peroxide with sodium orthovanadate
(Huyer et al., 1997). Given the potential
for unanticipated effects, we used our
FRET assay to examine the conse-
quences of pervanadate treatment on
CD33CD membrane binding (Xu et al.,
2008). The assay measures the interac-
tion of a TFP domain attached to the
C terminus of CD33CD with a lipophilic
dye R18 (octadecyl rhodamine B) incor-
porated in the plasma membrane; label-
ing the cells with R18 caused a decrease
in the TFP signal (quenching) due to
energy transfer from TFP to R18 (Fig-
ure S1C). In the absence of pervanadate,
the FRET efficiency was high (average
50%; Figure S1D), which is similar to
the FRET signal obtained with the positive
control in which TFP is positioned close
to the plasma membrane (a three amino
acid linker between the transmembrane
domain and TFP) (Xu et al., 2008). After
20 min of pervanadate treatment, the
FRET signal was reduced on average
to 15% (Figure S1D), similar to the
negative control with a 50 amino acid flex-
ible linker between the transmembrane
domain and TFP (Xu et al., 2008). Perva-
nadate treatment thus results in dissocia-
tion of the CD33 cytoplasmic domain from
the membrane.
We next examined the potential mech-
anisms that could contribute to this effect.
We had previously shown that basic resi-
dues of CD33CD are critical for its binding
to the plasma membrane. Therefore, wevier Inc.assessed whether the negative charge of
the inner leaflet of the plasma membrane
could be affected. Phosphatidylserine is
the most abundant negatively charged
lipid in the inner leaflet. We used a highly
specific calcium-independent phosphati-
dylserine probe, the Lactadherin C2
domain (Lact-C2), to study the dynamics
of phosphatidylserine distribution (Yeung
et al., 2008). Jurkat cells were transduced
with a lentivirus containing the Lact-C2
probe, and the probe’s localization in live
cells was analyzed by confocal micros-
copy (Figure S1E). Under resting condi-
tions, the Lact-C2 probe predominantly
associated with the plasma membrane in
75% of cells. In contrast, pervanadate
treatment reduced the Lact-C2 signal
at the plasma membrane and increased
the amount of this phosphatidylserine
probe in internal membranes in 92%
of cells, suggesting that the plasma
membrane inner leaflet had a reduced
negative charge (Figures S1E and S1F).
Phosphatidylserine at the cell surface
was also slightly increased, as measured
by annexin-V labeling (Figure S1G). We
conclude that pervanadate treatment
reduces the negative charge of the inner
leaflet and induces release of CD33CD
from the plasma membrane. These find-
ings complicate the interpretation of
experiments using pervanadate to assess
whether CD33CD is bound to the plasma
membrane.
A recent study confirmed that CD33CD
binds to the plasma membrane (Deford-
Watts et al., 2009), and prior work has
shown that CD3z is membrane bound
(Aivazian and Stern, 2000). Furthermore,
other cytoplasmic peptides have been
shown to interact with the inner leaflet
by similar mechanisms. McLaughlin and
colleagues showed that the MARCKS
peptide binds to the inner leaflet using
clusters of basic amino acids and five
phenylalanine residues (Zhang et al.,
2003). NMR measurements demon-
strated directly that these phenylalanine
residues are located in the hydrophobic
core of the lipid bilayer, similar to the tyro-
sines of CD33CD (Zhang et al., 2003).
Also, the cytoplasmic small GTPase Rit
localizes to the plasma membrane using
three clusters of basic amino acids
and interspersed hydrophobic residues;
mutation of a tryptophan in this segment
results in loss of membrane binding
(Heo et al., 2006). Therefore, usage of
both basic and hydrophobic residues
for plasma membrane binding is a more
general theme that extends beyond the
CD33 and z cytoplasmic domains of the
TCR-CD3 complex.
In their Correspondence, Fernandes
et al. raise questions about the functional
relevance of the binding of CD33CD to the
plasma membrane during TCR activation.
It will be important to further study the
functional significance of the binding of
CD33CD to the plasma membrane in
a physiological setting using primary
T cells because the early events in TCR
triggering are very complex, and subtle
changes may result in receptor activation
after ligand binding. Analysis of multiple
CD33CD mutant proteins will be useful,
including mutants with reduced rather
than complete loss of membrane binding.
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